<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4248">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272219</url>
  </required_header>
  <id_info>
    <org_study_id>NN8022-1839</org_study_id>
    <secondary_id>2008-001049-24</secondary_id>
    <secondary_id>U1111-1118-7871</secondary_id>
    <nct_id>NCT01272219</nct_id>
  </id_info>
  <brief_title>Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes</brief_title>
  <official_title>Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Austria: Austrian Federal Office for Safety in Health Care</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Ireland: Irish Medicines Board</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Belgium: Federal Agency for Medicines and Healthcare Products</authority>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>Hong Kong: Department of Health</authority>
    <authority>India: Ministry of Health</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>Mexico: National Commission for the Prevention of Sanitary Risks</authority>
    <authority>Russia: Federal Service for Control of Health Care and Social Development</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Serbia: Medicines and Medical Devices Agency of Serbia</authority>
    <authority>Poland: The Office for Reg. of Medicinal Products, Medical Devices and Biocidal Products - Central Register of Clinical Trials</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America.

      The aim of this clinical trial is to evaluate the potential of liraglutide to induce and
      maintain weight loss over 56 weeks in obese subjects or overweight subjects with
      co-morbidities. Furthermore, the aim is to investigate the long term potential of
      liraglutide to delay the onset of type 2 diabetes in subjects diagnosed with pre-diabetes at
      baseline.

      Based on body mass index (BMI) and pre-diabetes status, subjects will be randomised to
      either 68 weeks (56 weeks of randomised treatment followed by a 12 week re-randomised
      treatment period) or 160 weeks of treatment (160 week treatment will only be applicable to
      subjects with pre-diabetes status at baseline).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline in Fasting Body Weight</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <safety_issue>No</safety_issue>
    <description>The observed mean change from baseline in fasting body weight (%) after 56 weeks of treatment (main treatment period).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Subjects Losing at Least 5% of Baseline Fasting Body Weight.</measure>
    <time_frame>At Week 56</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects losing at least 5% of baseline fasting body weight in 56 weeks of treatment (main treatment period).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Subjects Losing More Than 10% of Baseline Fasting Body Weight.</measure>
    <time_frame>At 56 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects losing more than 10% of baseline fasting body weight in 56 weeks of treatment (main treatment period).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Subjects With Onset of Type 2 Diabetes</measure>
    <time_frame>at 160 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist Circumference (cm).</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <safety_issue>No</safety_issue>
    <description>The observed mean change from baseline in waist circumference (cm) after 56 weeks of treatment (main treatment period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist Circumference (Subjects With Pre-diabetes at Baseline)</measure>
    <time_frame>Week 0, week 160</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-diabetes Status After 56 Weeks of Treatment.</measure>
    <time_frame>Week 0, Week 56</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subject with no pre-diabetes and with pre-diabetes/diabetes after 56 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pre-diabetes Status (Subjects With Pre-diabetes at Baseline)</measure>
    <time_frame>Week 0, week 160</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Body Weight (Subjects With Pre-diabetes at Baseline)</measure>
    <time_frame>Week 0, week 160</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Losing at Least 5% and More Than 10% of Baseline Body Weight (Subjects With Pre-diabetes at Baseline)</measure>
    <time_frame>at 160 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Week 56 in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes).</measure>
    <time_frame>Week 56, Week 68</time_frame>
    <safety_issue>No</safety_issue>
    <description>The observed mean change in fasting body weight (%) from week 56 to week 68 of treatment, in re-randomised subjects with no pre-diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes).</measure>
    <time_frame>Week 0, Week 68</time_frame>
    <safety_issue>No</safety_issue>
    <description>The observed mean change from baseline in fasting body weight (%) after 68 weeks of treatment, in re-randomised subjects with no pre-diabetes at baseline.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">3731</enrollment>
  <condition>Metabolism and Nutrition Disorder</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide Placebo, no Pre-diabetes</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide 3.0mg, Pre-diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide Placebo, Pre-diabetes</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide 3.0 mg for 12 weeks (until week 68).</description>
    <arm_group_label>Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide placebo for 12 weeks (until week 68).</description>
    <arm_group_label>Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subject with no pre-diabetes at screening, receiving liraglutide placebo subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks, will continue to receive liraglutide placebo for 12 weeks (until week 68).</description>
    <arm_group_label>Liraglutide Placebo, no Pre-diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Liraglutide 3.0 mg, subcutaneous (under the skin) injection once daily for 160 weeks.</description>
    <arm_group_label>Liraglutide 3.0mg, Pre-diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Liraglutide placebo, subcutaneous (under the skin) injection once daily for 160 weeks.</description>
    <arm_group_label>Liraglutide Placebo, Pre-diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained

          -  Body Mass Index (BMI) of 30.0 kg/m^2 or above

          -  Body Mass Index (BMI) of 27 kg/m^2 or above in the presence of co-morbidities of
             treated or untreated dyslipidemia and/or hypertension

          -  Stable body weight (less than 5% selfreported change within the last 3 months)

          -  Preceding failed dietary effort

        Exclusion Criteria:

          -  Known type 1 or type 2 diabetes

          -  Glycosylated haemoglobin (HbA1c) of 6.5 % or above (Screening visit 1) or FPG of 126
             mg/dL (7 mmol/L) or above (Screening visit 2) or 2 hour post-challenge (OGTT) plasma
             glucose of 200 mg/dL (11.1 mmol/L) or above (Screening visit 2)

          -  Screening calcitonin of 50 ng/L or above

          -  Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial
             medullary thyroid carcinoma (FMTC)

          -  Personal history of non-familial medullary thyroid carcinoma

          -  History of acute or chronic pancreatitis

          -  Obesity induced by drug treatment

          -  Use of approved weight lowering pharmacotherapy

          -  Previous surgical treatment of obesity

          -  History of major depressive disorder or suicide attempt

          -  Uncontrolled hypertension (systolic blood pressure of 160 mmHg or above and/or
             diastolic blood pressure of 100 mmHg or above)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry GCR, 1452</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205-4731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-4140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036-5847</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Crystal River</city>
        <state>Florida</state>
        <zip>34429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <zip>30024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808-4124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>St. Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10301-3901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518-7414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Canal Fulton</city>
        <state>Ohio</state>
        <zip>44614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Wadsworth</city>
        <state>Ohio</state>
        <zip>44281-9236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620-7352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-4801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088-8871</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Henrico</city>
        <state>Virginia</state>
        <zip>23233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801-2028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boussu</city>
        <zip>7300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <zip>13073-350</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2T 5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frederiksberg C</city>
        <zip>1958</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <zip>01219</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin 9</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hengelo OV</city>
        <zip>7555 DL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>34760</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
  </removed_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 5, 2015</lastchanged_date>
  <firstreceived_date>January 6, 2011</firstreceived_date>
  <firstreceived_results_date>January 22, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted at 191 sites in 27 countries: Australia:4,Austria:3,Belgium:2, Brazil:5,Canada:11, Denmark:3,Finland:3, France:5, Germany:8,Hong Kong:1, Hungary:2, India:8, Ireland:1,Israel:7, Italy:7, Mexico:4, Netherlands:5, Norway:3, Poland:5, Russian:7, Serbia:2, South Africa:3, Spain:6, Switzerland:5,Turkey:40, UK:8, US:69.</recruitment_details>
      <pre_assignment_details>Eligible subjects were randomised in a 2:1 ratio to receive either liraglutide 3.0 mg or liraglutide placebo. Subjects were stratified based on pre-diabetes status at screening and further on baseline body mass index.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Liraglutide 3.0 mg, no Pre-diabetes</title>
          <description>Arm 1 (Arm 1A + Arm 1B): Subjects with no pre-diabetes at screening received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks followed by a re-randomisation (1:1 into liraglutide 3.0 mg or liraglutide placebo) period of 12 weeks (weeks 56-68) and then an off-drug follow-up period of 2 weeks. The total duration of this treatment arm from randomisation to follow-up was 70 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)</title>
          <description>Arm 1A: Subjects of Arm 1 (with no pre-diabetes at screening) receiving liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks were re-randomised (1:1 into liraglutide 3.0 mg or liraglutide placebo) to continue treatment with liraglutide 3.0 mg for the next 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period.</description>
        </group>
        <group group_id="P3">
          <title>Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)</title>
          <description>Arm 1B: Subjects of Arm 1 (with no pre-diabetes at screening) receiving liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks were re-randomised (1:1 into liraglutide 3.0 mg or liraglutide placebo) to receive liraglutide placebo for the next 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period.</description>
        </group>
        <group group_id="P4">
          <title>Liraglutide Placebo, no Pre-diabetes</title>
          <description>Arm 2: Subjects with no pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks and then continued with liraglutide placebo for additional 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period. The total duration of this treatment arm from randomisation to follow-up was 70 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Liraglutide 3.0 mg, Pre-diabetes</title>
          <description>Arm 3: Subjects with pre-diabetes at screening received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for initial 56 weeks then continued treatment till 160 weeks, followed by an off-drug, observational follow-up period of 12 weeks. The total duration of this treatment arm from randomisation to follow-up was 172 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Liraglutide Placebo, Pre-diabetes</title>
          <description>Arm 4: Subjects with pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for initial 56 weeks then continued treatment till 160 weeks, followed by an off-drug, observational follow-up period of 12 weeks. The total duration of this treatment arm from randomisation to follow-up was 172 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Period: Week 0 to Week 56</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="959"/>
                <participants group_id="P2" count="0">This arm is not considered for main period as these subjects belong to re-randomised period</participants>
                <participants group_id="P3" count="0">This arm is not considered for main period as these subjects belong to re-randomised period</participants>
                <participants group_id="P4" count="487"/>
                <participants group_id="P5" count="1528"/>
                <participants group_id="P6" count="757"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exposed</title>
              <participants_list>
                <participants group_id="P1" count="957"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="487"/>
                <participants group_id="P5" count="1524"/>
                <participants group_id="P6" count="755"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="679"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="296"/>
                <participants group_id="P5" count="1110"/>
                <participants group_id="P6" count="505"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="280"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="191"/>
                <participants group_id="P5" count="418"/>
                <participants group_id="P6" count="252"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="152"/>
                <participants group_id="P6" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="114"/>
                <participants group_id="P5" count="172"/>
                <participants group_id="P6" count="147"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="29"/>
                <participants group_id="P5" count="42"/>
                <participants group_id="P6" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Re-randomised Period: Week 56 to Week 68</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">This arm is not considered for re-randomised period as these subjects belong to main period.</participants>
                <participants group_id="P2" count="351">Due to incorrect stratification of subjects, some pre-diabetic subjects erroneously entered this arm</participants>
                <participants group_id="P3" count="350">Due to incorrect stratification of subjects, some pre-diabetic subjects erroneously entered this arm</participants>
                <participants group_id="P4" count="304">Due to incorrect stratification of subjects, some pre-diabetic subjects erroneously entered this arm</participants>
                <participants group_id="P5" count="0">This arm is not considered for re-randomised period as these subjects belong to main period.</participants>
                <participants group_id="P6" count="0">This arm is not considered for re-randomised period as these subjects belong to main period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="342"/>
                <participants group_id="P3" count="343"/>
                <participants group_id="P4" count="289"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liraglutide 3.0 mg, no Pre-diabetes</title>
          <description>Arm 1 (Arm 1A + Arm 1B): Subjects with no pre-diabetes at screening received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks followed by a re-randomisation (1:1 into liraglutide 3.0 mg or liraglutide placebo) period of 12 weeks (weeks 56-68) and then an off-drug follow-up period of 2 weeks. The total duration of this treatment arm from randomisation to follow-up was 70 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Liraglutide Placebo, no Pre-diabetes</title>
          <description>Arm 2: Subjects with no pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks and then continued with liraglutide placebo for additional 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period. The total duration of this treatment arm from randomisation to follow-up was 70 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Liraglutide 3.0 mg, Pre-diabetes</title>
          <description>Arm 3: Subjects with pre-diabetes at screening received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for initial 56 weeks then continued treatment till 160 weeks, followed by an off-drug, observational follow-up period of 12 weeks. The total duration of this treatment arm from randomisation to follow-up was 172 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Liraglutide Placebo, Pre-diabetes</title>
          <description>Arm 4: Subjects with pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for initial 56 weeks then continued treatment till 160 weeks, followed by an off-drug, observational follow-up period of 12 weeks. The total duration of this treatment arm from randomisation to follow-up was 172 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="959"/>
                <measurement group_id="B2" value="487"/>
                <measurement group_id="B3" value="1528"/>
                <measurement group_id="B4" value="757"/>
                <measurement group_id="B5" value="3731"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="41.6" spread="11.7"/>
                <measurement group_id="B2" value="41.5" spread="11.5"/>
                <measurement group_id="B3" value="47.4" spread="11.8"/>
                <measurement group_id="B4" value="47.2" spread="11.8"/>
                <measurement group_id="B5" value="45.1" spread="12.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="801"/>
                <measurement group_id="B2" value="390"/>
                <measurement group_id="B3" value="1156"/>
                <measurement group_id="B4" value="581"/>
                <measurement group_id="B5" value="2928"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="158"/>
                <measurement group_id="B2" value="97"/>
                <measurement group_id="B3" value="372"/>
                <measurement group_id="B4" value="176"/>
                <measurement group_id="B5" value="803"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Fasting Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="104.0" spread="20.1"/>
                <measurement group_id="B2" value="103.6" spread="21.2"/>
                <measurement group_id="B3" value="107.6" spread="21.8"/>
                <measurement group_id="B4" value="107.9" spread="21.8"/>
                <measurement group_id="B5" value="106.2" spread="21.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="37.5" spread="6.2"/>
                <measurement group_id="B2" value="37.4" spread="6.2"/>
                <measurement group_id="B3" value="38.8" spread="6.4"/>
                <measurement group_id="B4" value="39.0" spread="6.3"/>
                <measurement group_id="B5" value="38.3" spread="6.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Glycosylated Haemoglobin (HbA1c)</title>
          <units>percentage of glycosylated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="5.3" spread="0.3"/>
                <measurement group_id="B2" value="5.3" spread="0.3"/>
                <measurement group_id="B3" value="5.8" spread="0.3"/>
                <measurement group_id="B4" value="5.7" spread="0.3"/>
                <measurement group_id="B5" value="5.6" spread="0.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose (FPG)</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="5.0" spread="0.4"/>
                <measurement group_id="B2" value="5.1" spread="0.5"/>
                <measurement group_id="B3" value="5.5" spread="0.6"/>
                <measurement group_id="B4" value="5.5" spread="0.5"/>
                <measurement group_id="B5" value="5.3" spread="0.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Fasting Body Weight</title>
        <description>The observed mean change from baseline in fasting body weight (%) after 56 weeks of treatment (main treatment period).</description>
        <time_frame>Week 0, Week 56</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis set (FAS) included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg</title>
            <description>Subjects belong to Arm 1 (with no pre-diabetes at screening) and Arm 3 (with pre-diabetes at screening), received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide Placebo</title>
            <description>Subjects belong to Arm 2 (with no pre-diabetes at screening) and Arm 4 (with pre-diabetes at screening), received liraglutide Placebo, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2432"/>
                  <measurement group_id="O2" value="1220"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Fasting Body Weight</title>
            <description>The observed mean change from baseline in fasting body weight (%) after 56 weeks of treatment (main treatment period).</description>
            <units>percent change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-7.98" spread="6.67"/>
                  <measurement group_id="O2" value="-2.62" spread="5.74"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null-hypothesis: no treatment difference between treatment arms, i.e. liraglutide 3.0 mg and liraglutide placebo.
Liraglutide 3.0 mg was considered superior to placebo in inducing and maintaining weight loss, if the estimated treatment effect (liraglutide 3.0 mg – liraglutide placebo) was statistically significantly smaller than zero.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated mean difference</param_type>
            <param_value>-5.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.82</ci_lower_limit>
            <ci_upper_limit>-4.95</ci_upper_limit>
            <estimate_desc>ANCOVA model with treatment, country, sex, pre-diabetes status at screening, baseline BMI stratum and an interaction between pre-diabetes status at screening and BMI stratum as fixed factors, and the baseline value as covariate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects Losing at Least 5% of Baseline Fasting Body Weight.</title>
        <description>Proportion of subjects losing at least 5% of baseline fasting body weight in 56 weeks of treatment (main treatment period).</description>
        <time_frame>At Week 56</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis set (FAS) included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg</title>
            <description>Subjects belong to Arm 1 (with no pre-diabetes at screening) and Arm 3 (with pre-diabetes at screening), received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide Placebo</title>
            <description>Subjects belong to Arm 2 (with no pre-diabetes at screening) and Arm 4 (with pre-diabetes at screening), received liraglutide Placebo, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2432"/>
                  <measurement group_id="O2" value="1220"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proportion of Subjects Losing at Least 5% of Baseline Fasting Body Weight.</title>
            <description>Proportion of subjects losing at least 5% of baseline fasting body weight in 56 weeks of treatment (main treatment period).</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="63.2"/>
                  <measurement group_id="O2" value="27.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null-hypothesis: no treatment difference between treatment arms, i.e. liraglutide 3.0 mg and liraglutide placebo.
Liraglutide 3.0 mg was considered superior to placebo in inducing and maintaining weight loss as assessed by the proportion of subjects losing ≥5% of their fasting baseline weight, if the estimated odds ratio (liraglutide 3.0 mg/liraglutide placebo) was statistically significantly greater than one.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.12</ci_lower_limit>
            <ci_upper_limit>5.60</ci_upper_limit>
            <estimate_desc>The model includes treatment, country, sex, pre-diabetes status at screening, BMI stratum and an interaction between pre-diabetes status at screening and BMI stratum as fixed factors, and the baseline value as covariate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects Losing More Than 10% of Baseline Fasting Body Weight.</title>
        <description>Proportion of subjects losing more than 10% of baseline fasting body weight in 56 weeks of treatment (main treatment period).</description>
        <time_frame>At 56 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis set (FAS) included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg</title>
            <description>Subjects belong to Arm 1 (with no pre-diabetes at screening) and Arm 3 (with pre-diabetes at screening), received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide Placebo</title>
            <description>Subjects belong to Arm 2 (with no pre-diabetes at screening) and Arm 4 (with pre-diabetes at screening), received liraglutide Placebo, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2432"/>
                  <measurement group_id="O2" value="1220"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proportion of Subjects Losing More Than 10% of Baseline Fasting Body Weight.</title>
            <description>Proportion of subjects losing more than 10% of baseline fasting body weight in 56 weeks of treatment (main treatment period).</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33.1"/>
                  <measurement group_id="O2" value="10.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null-hypothesis: no treatment difference between treatment arms, i.e. liraglutide 3.0 mg and liraglutide placebo.
Liraglutide 3.0 mg was considered superior to placebo in inducing and maintaining weight loss as assessed by the proportion of subjects losing &gt;10% of their fasting baseline weight, if the estimated odds ratio (liraglutide 3.0 mg/liraglutide placebo) was statistically significantly greater than one.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.54</ci_lower_limit>
            <ci_upper_limit>5.32</ci_upper_limit>
            <estimate_desc>The model includes treatment, country, sex, pre-diabetes status at screening, BMI stratum and an interaction between pre-diabetes status at screening and BMI stratum as fixed factors, and the baseline value as covariate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects With Onset of Type 2 Diabetes</title>
        <time_frame>at 160 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist Circumference (cm).</title>
        <description>The observed mean change from baseline in waist circumference (cm) after 56 weeks of treatment (main treatment period).</description>
        <time_frame>Week 0, Week 56</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis set (FAS) included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg</title>
            <description>Subjects belong to Arm 1 (with no pre-diabetes at screening) and Arm 3 (with pre-diabetes at screening), received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide Placebo</title>
            <description>Subjects belong to Arm 2 (with no pre-diabetes at screening) and Arm 4 (with pre-diabetes at screening), received liraglutide Placebo, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2437"/>
                  <measurement group_id="O2" value="1225"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Waist Circumference (cm).</title>
            <description>The observed mean change from baseline in waist circumference (cm) after 56 weeks of treatment (main treatment period).</description>
            <units>cm</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-8.19" spread="7.31"/>
                  <measurement group_id="O2" value="-3.94" spread="6.58"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist Circumference (Subjects With Pre-diabetes at Baseline)</title>
        <time_frame>Week 0, week 160</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-diabetes Status After 56 Weeks of Treatment.</title>
        <description>Proportion of subject with no pre-diabetes and with pre-diabetes/diabetes after 56 weeks of treatment.</description>
        <time_frame>Week 0, Week 56</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis set (FAS) included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg</title>
            <description>Subjects belong to Arm 1 (with no pre-diabetes at screening) and Arm 3 (with pre-diabetes at screening), received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide Placebo</title>
            <description>Subjects belong to Arm 2 (with no pre-diabetes at screening) and Arm 4 (with pre-diabetes at screening), received liraglutide Placebo, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks, from randomisation.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2437"/>
                  <measurement group_id="O2" value="1225"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pre-diabetes Status After 56 Weeks of Treatment.</title>
            <description>Proportion of subject with no pre-diabetes and with pre-diabetes/diabetes after 56 weeks of treatment.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>With No Pre-diabetes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="78.3"/>
                  <measurement group_id="O2" value="50.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>With Pre-diabetes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.6"/>
                  <measurement group_id="O2" value="46.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>With Transient Type 2 Diabetes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.9"/>
                  <measurement group_id="O2" value="1.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>With Confirmed Type 2 Diabetes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.2"/>
                  <measurement group_id="O2" value="1.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pre-diabetes Status (Subjects With Pre-diabetes at Baseline)</title>
        <time_frame>Week 0, week 160</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Body Weight (Subjects With Pre-diabetes at Baseline)</title>
        <time_frame>Week 0, week 160</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Losing at Least 5% and More Than 10% of Baseline Body Weight (Subjects With Pre-diabetes at Baseline)</title>
        <time_frame>at 160 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Week 56 in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes).</title>
        <description>The observed mean change in fasting body weight (%) from week 56 to week 68 of treatment, in re-randomised subjects with no pre-diabetes.</description>
        <time_frame>Week 56, Week 68</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis set (FAS) included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)</title>
            <description>Arm 1A: Subjects of Arm 1 (with no pre-diabetes at screening) receiving liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks were re-randomised (1:1 into liraglutide 3.0 mg or liraglutide placebo) to continue treatment with liraglutide 3.0 mg for the next 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)</title>
            <description>Arm 1B: Subjects of Arm 1 (with no pre-diabetes at screening) receiving liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks were re-randomised (1:1 into liraglutide 3.0 mg or liraglutide placebo) to receive liraglutide placebo for the next 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide Placebo, no Pre-diabetes</title>
            <description>Arm 2: Subjects with no pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks and then continued with liraglutide placebo for additional 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period. The total duration of this treatment arm from randomisation to follow-up was 70 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="349"/>
                  <measurement group_id="O2" value="346"/>
                  <measurement group_id="O3" value="299"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Week 56 in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes).</title>
            <description>The observed mean change in fasting body weight (%) from week 56 to week 68 of treatment, in re-randomised subjects with no pre-diabetes.</description>
            <units>percent change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.69" spread="2.58"/>
                  <measurement group_id="O2" value="2.91" spread="3.01"/>
                  <measurement group_id="O3" value="0.28" spread="2.39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes).</title>
        <description>The observed mean change from baseline in fasting body weight (%) after 68 weeks of treatment, in re-randomised subjects with no pre-diabetes at baseline.</description>
        <time_frame>Week 0, Week 68</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis set (FAS) included all randomised subjects who were exposed to at least one dose of trial product (liraglutide 3.0 mg or liraglutide placebo) and who provided at least one post-baseline efficacy value. Missing data were imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)</title>
            <description>Arm 1A: Subjects of Arm 1 (with no pre-diabetes at screening) receiving liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks were re-randomised (1:1 into liraglutide 3.0 mg or liraglutide placebo) to continue treatment with liraglutide 3.0 mg for the next 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)</title>
            <description>Arm 1B: Subjects of Arm 1 (with no pre-diabetes at screening) receiving liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks were re-randomised (1:1 into liraglutide 3.0 mg or liraglutide placebo) to receive liraglutide placebo for the next 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide Placebo, no Pre-diabetes</title>
            <description>Arm 2: Subjects with no pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks and then continued with liraglutide placebo for additional 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period. The total duration of this treatment arm from randomisation to follow-up was 70 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="349"/>
                  <measurement group_id="O2" value="347"/>
                  <measurement group_id="O3" value="298"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes).</title>
            <description>The observed mean change from baseline in fasting body weight (%) after 68 weeks of treatment, in re-randomised subjects with no pre-diabetes at baseline.</description>
            <units>percent change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-8.44" spread="7.23"/>
                  <measurement group_id="O2" value="-6.77" spread="7.67"/>
                  <measurement group_id="O3" value="-3.11" spread="7.52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 0 to Week 68 + 2 weeks of follow-up: For Arm 1 and Arm 2 Week 0 to Week 56: For Arm 3 and Arm 4</time_frame>
      <desc>Safety analysis set includes all randomised subjects who had been exposed to at least one dose of the trial product. A total of 37 pre-diabetic subjects erroneously entered the re-randomised period and their adverse events were counted under the pre-diabetic arms.</desc>
      <group_list>
        <group group_id="E1">
          <title>Liraglutide 3.0 mg, no Pre-diabetes</title>
          <description>Arm 1 (Arm 1A + Arm 1B): Subjects with no pre-diabetes at screening received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks followed by a re-randomisation (1:1 into liraglutide 3.0 mg or liraglutide placebo) period of 12 weeks (weeks 56-68) and then an off-drug follow-up period of 2 weeks. The total duration of this treatment arm from randomisation to follow-up was 70 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Liraglutide Placebo, no Pre-diabetes</title>
          <description>Arm 2: Subjects with no pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks and then continued with liraglutide placebo for additional 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period. The total duration of this treatment arm from randomisation to follow-up was 70 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Liraglutide 3.0 mg, Pre-diabetes</title>
          <description>Arm 3: Subjects with pre-diabetes at screening received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for initial 56 weeks then continued treatment till 160 weeks, followed by an off-drug, observational follow-up period of 12 weeks. The total duration of this treatment arm from randomisation to follow-up was 172 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Liraglutide Placebo, Pre-diabetes</title>
          <description>Arm 4: Subjects with pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for initial 56 weeks then continued treatment till 160 weeks, followed by an off-drug, observational follow-up period of 12 weeks. The total duration of this treatment arm from randomisation to follow-up was 172 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="957"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="487"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="1524"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Hypercoagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Multiple endocrine adenomatosis Type I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Barrett</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Caecitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="1524"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Oophoritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Post laminectomy syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Joint laxity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Breast cancer stage III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the small bowel</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Haemangioma of bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Hepatic adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma stage I</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Vaginal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>IgA nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa uteri cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Endometrial disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Panniculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Coronary revascularisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Gastrectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Varicophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="957"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1524"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="828" subjects_at_risk="957"/>
                <counts group_id="E2" subjects_affected="328" subjects_at_risk="487"/>
                <counts group_id="E3" subjects_affected="1236" subjects_at_risk="1524"/>
                <counts group_id="E4" subjects_affected="503" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="79" subjects_affected="62" subjects_at_risk="957"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="487"/>
                <counts group_id="E3" events="87" subjects_affected="71" subjects_at_risk="1524"/>
                <counts group_id="E4" events="34" subjects_affected="26" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="84" subjects_affected="63" subjects_at_risk="957"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="487"/>
                <counts group_id="E3" events="91" subjects_affected="80" subjects_at_risk="1524"/>
                <counts group_id="E4" events="29" subjects_affected="24" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="255" subjects_affected="203" subjects_at_risk="957"/>
                <counts group_id="E2" events="52" subjects_affected="44" subjects_at_risk="487"/>
                <counts group_id="E3" events="355" subjects_affected="301" subjects_at_risk="1524"/>
                <counts group_id="E4" events="74" subjects_affected="67" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="308" subjects_affected="201" subjects_at_risk="957"/>
                <counts group_id="E2" events="57" subjects_affected="45" subjects_at_risk="487"/>
                <counts group_id="E3" events="467" subjects_affected="325" subjects_at_risk="1524"/>
                <counts group_id="E4" events="88" subjects_affected="71" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="121" subjects_affected="102" subjects_at_risk="957"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="487"/>
                <counts group_id="E3" events="163" subjects_affected="135" subjects_at_risk="1524"/>
                <counts group_id="E4" events="29" subjects_affected="26" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="52" subjects_affected="38" subjects_at_risk="957"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E3" events="92" subjects_affected="83" subjects_at_risk="1524"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="616" subjects_affected="418" subjects_at_risk="957"/>
                <counts group_id="E2" events="95" subjects_affected="77" subjects_at_risk="487"/>
                <counts group_id="E3" events="833" subjects_affected="584" subjects_at_risk="1524"/>
                <counts group_id="E4" events="136" subjects_affected="112" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="266" subjects_affected="172" subjects_at_risk="957"/>
                <counts group_id="E2" events="29" subjects_affected="25" subjects_at_risk="487"/>
                <counts group_id="E3" events="339" subjects_affected="234" subjects_at_risk="1524"/>
                <counts group_id="E4" events="36" subjects_affected="29" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="89" subjects_affected="79" subjects_at_risk="957"/>
                <counts group_id="E2" events="31" subjects_affected="27" subjects_at_risk="487"/>
                <counts group_id="E3" events="120" subjects_affected="111" subjects_at_risk="1524"/>
                <counts group_id="E4" events="42" subjects_affected="39" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" events="68" subjects_affected="64" subjects_at_risk="957"/>
                <counts group_id="E2" events="45" subjects_affected="42" subjects_at_risk="487"/>
                <counts group_id="E3" events="87" subjects_affected="79" subjects_at_risk="1524"/>
                <counts group_id="E4" events="56" subjects_affected="51" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="41" subjects_affected="35" subjects_at_risk="957"/>
                <counts group_id="E2" events="27" subjects_affected="26" subjects_at_risk="487"/>
                <counts group_id="E3" events="59" subjects_affected="55" subjects_at_risk="1524"/>
                <counts group_id="E4" events="38" subjects_affected="33" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="53" subjects_affected="48" subjects_at_risk="957"/>
                <counts group_id="E2" events="32" subjects_affected="24" subjects_at_risk="487"/>
                <counts group_id="E3" events="84" subjects_affected="75" subjects_at_risk="1524"/>
                <counts group_id="E4" events="26" subjects_affected="24" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="81" subjects_affected="65" subjects_at_risk="957"/>
                <counts group_id="E2" events="37" subjects_affected="26" subjects_at_risk="487"/>
                <counts group_id="E3" events="106" subjects_affected="91" subjects_at_risk="1524"/>
                <counts group_id="E4" events="54" subjects_affected="44" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="290" subjects_affected="193" subjects_at_risk="957"/>
                <counts group_id="E2" events="165" subjects_affected="109" subjects_at_risk="487"/>
                <counts group_id="E3" events="353" subjects_affected="259" subjects_at_risk="1524"/>
                <counts group_id="E4" events="174" subjects_affected="136" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="99" subjects_affected="84" subjects_at_risk="957"/>
                <counts group_id="E2" events="47" subjects_affected="35" subjects_at_risk="487"/>
                <counts group_id="E3" events="64" subjects_affected="60" subjects_at_risk="1524"/>
                <counts group_id="E4" events="57" subjects_affected="43" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="121" subjects_affected="100" subjects_at_risk="957"/>
                <counts group_id="E2" events="68" subjects_affected="54" subjects_at_risk="487"/>
                <counts group_id="E3" events="158" subjects_affected="134" subjects_at_risk="1524"/>
                <counts group_id="E4" events="98" subjects_affected="78" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="60" subjects_affected="48" subjects_at_risk="957"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="487"/>
                <counts group_id="E3" events="88" subjects_affected="69" subjects_at_risk="1524"/>
                <counts group_id="E4" events="24" subjects_affected="18" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="41" subjects_affected="35" subjects_at_risk="957"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="487"/>
                <counts group_id="E3" events="92" subjects_affected="81" subjects_at_risk="1524"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="111" subjects_affected="102" subjects_at_risk="957"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="487"/>
                <counts group_id="E3" events="174" subjects_affected="166" subjects_at_risk="1524"/>
                <counts group_id="E4" events="22" subjects_affected="22" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="299" subjects_affected="175" subjects_at_risk="957"/>
                <counts group_id="E2" events="37" subjects_affected="29" subjects_at_risk="487"/>
                <counts group_id="E3" events="195" subjects_affected="145" subjects_at_risk="1524"/>
                <counts group_id="E4" events="22" subjects_affected="20" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="38" subjects_at_risk="957"/>
                <counts group_id="E2" events="29" subjects_affected="23" subjects_at_risk="487"/>
                <counts group_id="E3" events="94" subjects_affected="90" subjects_at_risk="1524"/>
                <counts group_id="E4" events="53" subjects_affected="49" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="95" subjects_affected="77" subjects_at_risk="957"/>
                <counts group_id="E2" events="50" subjects_affected="41" subjects_at_risk="487"/>
                <counts group_id="E3" events="129" subjects_affected="103" subjects_at_risk="1524"/>
                <counts group_id="E4" events="76" subjects_affected="66" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="81" subjects_affected="67" subjects_at_risk="957"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="487"/>
                <counts group_id="E3" events="132" subjects_affected="108" subjects_at_risk="1524"/>
                <counts group_id="E4" events="45" subjects_affected="41" subjects_at_risk="755"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="178" subjects_affected="127" subjects_at_risk="957"/>
                <counts group_id="E2" events="80" subjects_affected="58" subjects_at_risk="487"/>
                <counts group_id="E3" events="282" subjects_affected="208" subjects_at_risk="1524"/>
                <counts group_id="E4" events="144" subjects_affected="96" subjects_at_risk="755"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>When the primary results are available, Novo Nordisk plans to discuss the interpretation of these with the principal Investigator, but reserves the right to release results that may impact Novo Nordisk financial expectations (e.g. a press release directly to the public or similar) without prior consultation with the remaining participating Investigators. Novo Nordisk reserves the right not to release data until specified milestones, e.g. a clinical trial report is available.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
